Lupin receives tentative approval for Empagliflozin and Linagliptin Tablets

Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of Glyxambi® Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (RLD: Glyxambi®) had an annual sales of approximately USD 242 million in the U.S. (IQVIA MAT Mar 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.862.85 as compared to the previous close of Rs. 851.15. The total number of shares traded during the day was 78036 in over 2984 trades.

The stock hit an intraday high of Rs. 864.55 and intraday low of 851.2. The net turnover during the day was Rs. 67059770.

Source : Equity Bulls

Keywords